. 2021 Aug 31;92(4):1797–1815. doi: 10.1007/s11126-021-09930-x

Table 2.

TRD prevalence among patients with MDD by type of care site, overall and by country^a

	Total MDD population (N = 1475)	Mexico (n = 697)	Colombia (n = 162)	Brazil (n = 396)	Argentina (n = 220)
Private sites of care	202 (27.1%) [23.9%–30.3%]	78 (22.3%) [17.9%–26.6%]	41 (35.3%) [26.2%–44.0%]	10 (16.7%) [7.2%–26.1%]	73 (33.2%) [27.0%–39.4%]
Public sites of care	227 (31.1%) [27.8%–34.5%]	66 (19.0%) [14.9%–23.1%]	11 (23.9%) [11.6%–36.2%]	150 (44.6%) [39.3%–50.0%]	–

Total MDD population
(N = 1475)

Mexico
(n = 697)

Colombia
(n = 162)

Brazil
(n = 396)

Argentina
(n = 220)

Private sites of care

202 (27.1%)

[23.9%–30.3%]

78 (22.3%)

[17.9%–26.6%]

41 (35.3%)

[26.2%–44.0%]

10 (16.7%)

[7.2%–26.1%]

73 (33.2%)

[27.0%–39.4%]

Public sites of care

227 (31.1%)

[27.8%–34.5%]

66 (19.0%)

[14.9%–23.1%]

11 (23.9%)

[11.6%–36.2%]

150 (44.6%)

[39.3%–50.0%]

–

TRD treatment-resistant depression, MDD major depressive disorder, CI confidence interval

^aData are reported as prevalence (95% CI). Prevalence is based on the total numbers of patients from private or public sites of care, as appropriate. These values for private and public sites of care, respectively, were: 746 and 729 (total MDD population), 350 and 347 (Mexico), 116 and 46 (Colombia), 60 and 336 (Brazil), and 220 (Argentina [private sites of care only])